MRI radiomics model for predicting TERT promoter mutation status in glioblastoma

被引:4
|
作者
Chen, Ling [1 ,2 ]
Chen, Runrong [1 ]
Li, Tao [2 ]
Huang, Lizhao [2 ]
Tang, Chuyun [1 ]
Li, Yao [3 ]
Zeng, Zisan [1 ]
机构
[1] Guangxi Med Univ, Affiliated Hosp 1, Dept Radiol, Nanning, Guangxi, Peoples R China
[2] Guangxi Med Univ, Liuzhou Workers Hosp, Affiliated Hosp 4, Dept Radiol, Nanning, Guangxi, Peoples R China
[3] Guangxi Med Univ, Liuzhou Workers Hosp, Affiliated Hosp 4, Dept Neurosurg, Nanning, Guangxi, Peoples R China
来源
BRAIN AND BEHAVIOR | 2023年 / 13卷 / 12期
关键词
glioblastoma; magnetic resonance imaging; radiomics; TERT; IDH MUTATION; METHYLATION; FEATURES; GLIOMAS;
D O I
10.1002/brb3.3324
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Background and purposeThe presence of TERT promoter mutations has been associated with worse prognosis and resistance to therapy for patients with glioblastoma (GBM). This study aimed to determine whether the combination model of different feature selections and classification algorithms based on multiparameter MRI can be used to predict TERT subtype in GBM patients.MethodsA total of 143 patients were included in our retrospective study, and 2553 features were obtained. The datasets were randomly divided into training and test sets in a ratio of 7:3. The synthetic minority oversampling technique was used to achieve data balance. The Pearson correlation coefficients were used for dimension reduction. Three feature selections and five classification algorithms were used to model the selected features. Finally, 10-fold cross validation was applied to the training dataset.ResultsA model with eight features generated by recursive feature elimination (RFE) and linear discriminant analysis (LDA) showed the greatest diagnostic performance (area under the curve values for the training, validation, and testing sets: 0.983, 0.964, and 0.926, respectively), followed by relief and random forest (RF), analysis of variance and RF. Furthermore, the relief was the optimal feature selection for separately evaluating those five classification algorithms, and RF was the most preferable algorithm for separately assessing the three feature selectors. ADC entropy was the parameter that made the greatest contribution to the discrimination of TERT mutations.ConclusionsRadiomics model generated by RFE and LDA mainly based on ADC entropy showed good performance in predicting TERT promoter mutations in GBM. Adult glioblastoma (GBM) is the most common and aggressive primary brain tumor, with a high recurrence and mortality rate. The presence of TERT promoter mutations has been associated with poor prognosis and resistance to therapy, making it an important biomarker for personalized treatment strategies. In this study, we investigated the relationship between multiparameter MRI features and TERT mutation status, establishing a radiomics signature for predicting TERT promoter mutation status, and verified its effectiveness in prognostic assessment with GBM patients. image
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Feasibility of MRI Radiomics for Predicting KRAS Mutation in Rectal Cancer
    Xiao-fang Guo
    Wen-qian Yang
    Qian Yang
    Zi-long Yuan
    Yu-lin Liu
    Xiao-hui Niu
    Hai-bo Xu
    Current Medical Science, 2020, 40 : 1156 - 1160
  • [22] Feasibility of MRI Radiomics for Predicting KRAS Mutation in Rectal Cancer
    Guo, Xiao-fang
    Yang, Wen-qian
    Yang, Qian
    Yuan, Zi-long
    Liu, Yu-lin
    Niu, Xiao-hui
    Xu, Hai-bo
    CURRENT MEDICAL SCIENCE, 2020, 40 (06): : 1156 - 1160
  • [23] Editorial for "Predicting Isocitrate Dehydrogenase (IDH) Mutation Status in Gliomas Using Multiparameter MRI Radiomics Features"
    Kugel, Harald
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2021, 53 (05) : 1408 - 1409
  • [24] Predicting TERT promoter mutation using MR images in patients with witd-type IDH1 glioblastoma
    Yamashita, K.
    Hatae, R.
    Hiwatashi, A.
    Togao, O.
    Kikuchi, K.
    Momosaka, D.
    Yamashita, Y.
    Kuga, D.
    Hata, N.
    Yoshimoto, K.
    Suzuki, S. O.
    Iwaki, T.
    Iihara, K.
    Honda, H.
    DIAGNOSTIC AND INTERVENTIONAL IMAGING, 2019, 100 (7-8) : 411 - 419
  • [25] MRI-based radiomics model for predicting endometrial cancer with high tumor mutation burden
    Meng, Xuxu
    Yang, Dawei
    Jin, He
    Xu, Hui
    Lu, Jun
    Liu, Zhenhao
    Wang, Zhenchang
    Wang, Liang
    Yang, Zhenghan
    ABDOMINAL RADIOLOGY, 2024, : 1822 - 1830
  • [26] TERT Promoter Mutation Status in Morphological Variants of Urothelial Carcinoma
    Pradhan, D.
    Ernst, W. L.
    Mercurio, S.
    De Moura, M. Barbi
    Nikiforova, M.
    Dhir, R.
    Roy, S.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2017, 19 (06): : 1018 - 1018
  • [27] Multiregional radiomics profiling from multiparametric MRI: Identifying an imaging predictor of IDH1 mutation status in glioblastoma
    Li, Zhi-Cheng
    Bai, Hongmin
    Sun, Qiuchang
    Zhao, Yuanshen
    Lv, Yanchun
    Zhou, Jian
    Liang, Chaofeng
    Chen, Yinsheng
    Liang, Dong
    Zheng, Hairong
    CANCER MEDICINE, 2018, 7 (12): : 5999 - 6009
  • [28] REVERSAL OF GLIOBLASTOMA REPLICATIVE IMMORTALITY IN A TERT PROMOTER MUTATION-DEPENDENT MANNER
    Mancini, Andrew
    Xavier-Magalhaes, Ana
    Woods, Wendy
    Nguyen, Kien-Thiet
    Amen, Alexandra
    McKinney, Andrew
    Hayes, Josie
    Song, Jun
    Costa, Bruno
    Perez-Pinera, Pablo
    Costello, Joseph
    NEURO-ONCOLOGY, 2017, 19 : 57 - 58
  • [29] Mutation Analysis of the TERT Promoter in Hepatoblastoma and Glioblastoma by Sanger Sequencing and Pyrosequencing Assays
    Sarabia, S. F.
    Mehta, V. P.
    Tran, M. T.
    Fisher, K. E.
    Adesina, A. M.
    Finegold, M. J.
    Lopez-Terrada, D. H.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (06): : 827 - 828
  • [30] Radiomics and visual analysis for predicting success of transplantation of heterotopic glioblastoma in mice with MRI
    Wagner, Sabine
    Ewald, Christian
    Freitag, Diana
    Herrmann, Karl-Heinz
    Koch, Arend
    Bauer, Johannes
    Vogl, Thomas J.
    Kemmling, Andre
    Gufler, Hubert
    JOURNAL OF NEURO-ONCOLOGY, 2024, 169 (02) : 257 - 267